Successful treatment with ceritinib after crizotinib induced hepatitis

Sassier, Marion; Mennecier, B.; Gschwend, Anthony; Rein, Mikahl; Coquerel, Antoine; Humbert, Xavier; Alexandre, Jonas; Fédrizzi, Sophie; Gervais, Radj

doi:10.1016/j.lungcan.2016.02.008

Cited by 14 publications

(14 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although cholangitis was not clear, other etiologies were difficult to consider, and therefore, treatment was commenced with empirical antibiotics. Although acute hepatitis has been reported to be associated with crizotinib therapy, cholangitis or cholestasis have not previously been described. The other type of ALK inhibitor, ceritinib, has been reported to cause cholestasis with intrahepatic bile duct dilatation similar to our case .…”

Section: Discussionsupporting

confidence: 81%

ALK‐positive lung cancer diagnosed with abdominal lymph nodes in a patient receiving hemodialysis

et al. 2019

View full text Add to dashboard Cite

There is little consensus in the literature about the administration of crizotinib in patients with end‐stage renal disease undergoing hemodialysis. A 69‐year‐old male patient, who was receiving regular hemodialysis due to end‐stage renal disease, visited the hospital with symptoms of repeated abdominal pain. There was no suspicious finding of cancer within the thorax. After biopsy, the abdominal lymph nodes were identified as adenocarcinoma originating from the lung following computed tomography (CT) scan, and ALK rearrangement was confirmed. The patient achieved a partial response following the administration of crizotinib, although treatment was discontinued because of unknown cholestasis. Overall survival was eight months. Although crizotinib has clear efficacy in patients with ALK‐positive lung cancer with end‐stage renal disease, the optimal dose of crizotinib should be identified in patients receiving regular hemodialysis.

show abstract

Section: Discussionsupporting

confidence: 81%

ALK‐positive lung cancer diagnosed with abdominal lymph nodes in a patient receiving hemodialysis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…No infections were demonstrated, and other possible causes were excluded by imaging and blood tests. We concluded this might be a case of drug‐induced liver injury (Hy's Law), as already reported for others ALK inibitors . Moreover, tyrosine kinase inhibitors (TKIs) can inhibit paracetamol glucuronidation, and the interaction of the two drugs may have played a role in our patient, who was taking paracetamol for preexisting “abdominal pain” .…”

Section: Case Reportssupporting

confidence: 74%

“…We concluded this might be a case of drug-induced liver injury (Hy's Law), as already reported for others ALK inibitors. 10,11 Moreover, tyrosine kinase inhibitors (TKIs) can inhibit paracetamol glucuronidation, and the interaction of the two drugs may have played a role in our patient, who was taking paracetamol for preexisting "abdominal pain". 12 Despite extensive infectious work-up which was negative, a viral infection may also have played a role, as the patient was suffering from a common cold.…”

Section: Patientmentioning

confidence: 95%

ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects

Brivio

Zwaan

2019

Pediatric Blood & Cancer

View full text Add to dashboard Cite

There is an increasing interest for anaplastic lymphoma kinase (ALK) inhibitors in pediatric oncology for specific entities such as ALK‐driven inflammatory myofibroblastic tumor (IMT). IMT treatment can be challenging due to localization of the tumor and in rare cases of metastasis. When standard surgical treatment is not feasible, ALK inhibitors may play an important role, as recently reported for the first‐generation ALK inhibitors (crizotinib). However, data on the second‐generation ALK inhibitors are limited. We report two emblematic cases of IMT in pediatric patients, treated with the second‐generation ALK inhibitor ceritinib in the context of a clinical trial (NCT01742286).

show abstract

“…A previous case report reported successful treatment with ceritinib following crizotinib-induced hepatitis (8). Therefore, these novel ALK inhibitors may be additional options for the management of crizotinib-induced hepatitis.…”

Section: Discussionmentioning

confidence: 98%

“…Grade 3-4 ALT elevations occur in ~15% of NSCLC patients with ALK rearrangement mutations (2,5). Three cases of crizotinib-induced hepatitis have been reported, all of which occurred within a few months after the introduction of crizotinib (6)(7)(8). In one of those cases, rechallenge with half-dose crizotinib failed due to recurrence of hepatitis (6).…”

Section: Discussionmentioning

confidence: 99%

Successful oral desensitization with crizotinib after crizotinib‑induced hepatitis in an anaplastic lymphoma kinase‑rearranged non‑small‑cell lung cancer patient: A case report

et al. 2017

View full text Add to dashboard Cite

Abstract. Crizotinib is one of the molecularly-targeted agents targeted against anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC). Although its effects appear to be promising, crizotinib may cause adverse effects in patients with ALK-rearranged NSCLC. Hepatic laboratory abnormalities are frequently observed with crizotinib and treatment discontinuation is occasionally required. We herein report the case of a 51-year-old woman diagnosed with relapsed ALK-rearranged NSCLC, who received crizotinib as second-line systemic chemotherapy. After 17 days of crizotinib therapy, the patient developed grade >3 hepatotoxicity. Treatment discontinuation improved the laboratory abnormalities and fifth-line oral desensitization with crizotinib achieved successful response without hepatotoxicity. Therefore, oral desensitization with crizotinib may be a viable option following crizotinib-induced hepatitis.

show abstract

Successful treatment with ceritinib after crizotinib induced hepatitis

Cited by 14 publications

References 4 publications

ALK‐positive lung cancer diagnosed with abdominal lymph nodes in a patient receiving hemodialysis

ALK‐positive lung cancer diagnosed with abdominal lymph nodes in a patient receiving hemodialysis

ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects

Successful oral desensitization with crizotinib after crizotinib‑induced hepatitis in an anaplastic lymphoma kinase‑rearranged non‑small‑cell lung cancer patient: A case report

Contact Info

Product

Resources

About